ClinicalTrials.gg
TerminatedNCT04835220Updated Oct 2, 2026

Trial of Oral Lenalidomide Stewardship Program for Veterans

An interventional study of Telehealth Calls in Medication Compliance, sponsored by W.G. Bill Hefner Medical Center. Terminated at 1 site in United States. Per ClinicalTrials.gov, last updated 2026-10-02.

Sponsored by W.G. Bill Hefner Medical Center · Not applicable, Interventional, and Supportive care

How we know

Why this study was terminated
withdrawn due to funding and poor accrual
Updated Sep 29, 2026Now TerminatedPrimary completion moved+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
40
Allocation
Randomized
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 463 studies in Medication Adherence with a site in United States — 59 open to participants now, 74 under way, 1 of them phase 3. Medication Adherence · United States.

Enrollment
308th of 422
40 · median 96
Started
2021
with 25 others
No phase
368 of 463
53 open now
Registered
337th of 463
by date

Among the 463 studies in Medication Adherence with a site in United States, this one is the 308th largest by enrollment of the 422 interventional ones that give a count, is one of 26 that started in 2021, is one of 368 with no phase, and was the 337th registered.

Medication Adherence

943 studies on the registry are indexed under Medication Adherence; 162 are open to participants now.

Browse Medication Adherence studies →

Open to participants now

59 of the 463 studies in Medication Adherence with a site in United States are open now. Recruiting first, the newest first:

54 more — sign in →

All 59 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 81 Medication Adherence studies recruiting now, 52 (64%) set no upper age limit and 21 (26%) stop at 75 or younger; 15 take children under 18; 12 take healthy volunteers.

This study: all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 463 studies in Medication Adherence with a site in United States, or all of them as a file.
02

Study summary

To address the challenge of oral chemotherapy stewardship in the Veteran population, this study outlines the implementation and evaluation of a pilot program for the delivery and management of lenalidomide to increase the adherence rates. Our goal is to utilize a team-based multi-disciplinary approach using existing technological resources such as the tele-oncology program at the Salisbury VA and other VA medical centers to provide cancer care that is safe, effective, compassionate, and cost-effective. Subject will be prescribed a Lenalidomide based therapy per standard of care. Eligibility is based only on a prescription for Lenalidomide and is independent of any other concurrent treatments for myeloma. The objectives are as followed: 1. To describe the demographics and baseline clinical characteristics of veterans with newly diagnosed multiple myeloma treated with oral lenalidomide. 2. To evaluate the impact of the stewardship program (intervention) on the adherence to oral lenalidomide.

03

Conditions studied

  • Medication Compliance

Browse trials for

04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Newly diagnosed with myeloma or Initiating lenalidomide maintenance therapy after transplant or transplant ineligible patients that are started on lenalidomide until progression or intolerance.
  • Myeloma diagnosis (International Classification of Diseases, Tenth Revision, Clinical Modification [ICD-10-CM] codes:vC90.00 or associated diagnosis )
  • Prescription for lenalidomide
  • Planned or Currently treated with lenalidomide as part of a treatment regimen for newly diagnosed myeloma
  • Renal function assessed by calculated as follows (see Appendix: Cockcroft-Gault estimation of CrCl):

Subjects must have calculated creatinine clearance ≥ 30ml/min by Cockcroft-Gault formula. (See Appendix C). Dosing for patients with creatinine clearance between 30ml/min-60ml/min will be based on lenalidomide package insert.

  • Total 1.5 x
  • (SGOT) and ALT (SGPT) 3 x ULN.
  • All study participants must be registered into the mandatory Revlimid REMS® program, and be willing and able to comply with the requirements of the REMS® program.
  • Females of must adhere to the scheduled pregnancy testing as required in the Revlimid REMS® program.
  • Able to take prophylactic anticoagulation such as aspirin, warfarin, low molecular weight heparin or direct oral anticoagulant.
  • Personal Computer with internet Capability.

Exclusion criteria

Exclusion Criteria:

  • \< 18 years of age as of the index date
  • Newly diagnosed with myeloma and not started on lenalidomide
  • Known to thalidomide or lenalidomide (if applicable).
  • The development of erythema nodosum if characterized by a desquamating rash while taking thalidomide or similar drugs.
  • Known seropositive for or active viral infection with (HIV), virus (HBV) or virus (HCV). Patients who are seropositive because of hepatitis B virus vaccine are eligible.
  • Females who are pregnant.
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
40 participants (actual)

Study arms

  • No intervention
    Control Group

    Electronic pill bottle cap (MEMs bottle cap) with no Telehealth calls

  • Other
    Telehealth intervention group

    Electronic pill bottle cap (MEMs bottle cap) with regular telehealth visits to the veterans at the VAMCs on the stewardship program. These visits will involve contacting the veterans by telephone, administering a questionnaire to review their medication-taking behavior for oral chemotherapy, and potentially contacting the treating oncologist in the event that the veterans are at risk of non-adherence (based on their responses).

    Other: Telehealth Calls

Interventions

  • OtherTelehealth Calls

    The telehealth nurse will record data in a case report form within the VA REDCap electronic data capture system that is stored within the VA firewall.

06

What researchers measure

Primary outcomes

  1. Adherence of medication compliance

    To evaluate the impact of the stewardship program (intervention) on the adherence to oral lenalidomide. Adherence of veterans to their prescribed lenalidomide treatment will be measured based on MEMs bottle cap data. A descriptive analysis using data from the MGL Scale (asked during the telehealth call) will be conducted to describe adherence in the stewardship assistance program cohort. Of note, patients in the intervention arm who stop attending telehealth calls prior to the completion of the patient stewardship program will still be considered as part of the intervention arm (i.e., an "intent-to-treat analysis"). However, data on the participation in the patient stewardship program (e.g., number of telehealth visits attended), will be collected and may be used in sensitivity analyses if appropriate.

    Time frame: 12 Months

Secondary outcomes

  1. Clinical Characteristics

    Describe the demographics and baseline clinical characteristics of veterans with newly diagnosed multiple myeloma treated with oral lenalidomide.

    Time frame: 12 months

07

Study locations

1 site
  • W.G. Bill Hefner VAMC
    Salisbury, North Carolina 28144, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Ran from Mar 2021 to primary completion in Jun 2023, 26 months.

Since we started tracking on Sep 25, 2026, the dates moved once, on Sep 29, 2026: primary completion Mar 2024 → Jun 2023 and completion Mar 2024 → Jun 2023.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Apr 2, 2021
First posted
Apr 8, 2021
StartActual
Mar 26, 2021
Primary completionActual
Jun 20, 2023was Mar 2024
CompletionActual
Jun 20, 2023was Mar 2024
Last update
Oct 2, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Status unknown→Terminated withdrawn due to funding and poor accrual
changed Sep 29, 2026
Primary completion
Mar 26, 2024→Jun 20, 2023 (actual)
Sep 29, 2026
Study completion
Mar 26, 2024→Jun 20, 2023 (actual)
Sep 29, 2026
Show all 1 update
  1. Sep 29, 2026
    Status unknown→Terminated
    Why stopped withdrawn due to funding and poor accrual
    Primary completion Mar 26, 2024→Jun 20, 2023 (now actual)
    Study completion Mar 26, 2024→Jun 20, 2023 (now actual)
    + 3 other changes: verification date, responsible party and index terms

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT04835220
Lead sponsor
W.G. Bill Hefner Medical Center
Responsible party
Sponsor
First posted
Apr 8, 2021
Start date
Mar 26, 2021
Primary completion
Jun 20, 2023
Completion
Jun 20, 2023
Last update
Oct 2, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion